about
Self management for patients with chronic obstructive pulmonary diseaseEffect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trialAffective descriptors of the sensation of breathlessness are more highly associated with severity of impairment than physical descriptors in people with COPD.Which chronic obstructive pulmonary disease care recommendations have low implementation and why? A pilot studyDevelopment of a self-treatment approach for patients with COPD and comorbidities: an ongoing learning process.Systematic assessment of clinical practice guidelines for the management of chronic obstructive pulmonary disease.Why are some evidence-based care recommendations in chronic obstructive pulmonary disease better implemented than others? Perspectives of medical practitionersRandomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoeaCurrent care services provided for patients with COPD in the Eastern province in Saudi Arabia: a descriptive study.SA HealthPlus: a controlled trial of a statewide application of a generic model of chronic illness careConstruct Validity of the Dutch Version of the 12-Item Partners in Health Scale: Measuring Patient Self-Management Behaviour and Knowledge in Patients with Chronic Obstructive Pulmonary DiseaseHeliox, dyspnoea and exercise in COPD.Treatments for anxiety and depression in patients with chronic obstructive pulmonary disease: a literature review.The predictive value of an adjusted COPD assessment test score on the risk of respiratory-related hospitalizations in severe COPD patients.COPD care in Saudi Arabia: physicians' awareness and knowledge of guidelines and barriers to implementation.Definition of a COPD self-management intervention: International Expert Group consensus.Feasibility of ω-3 fatty acid supplementation as an adjunct therapy for people with chronic obstructive pulmonary disease: study protocol for a randomized controlled trial.Barriers for setting up a pulmonary rehabilitation program in the Eastern Province of Saudi ArabiaIntegrated care pathways for airway diseases (AIRWAYS-ICPs).Frequency of referral to and attendance at a pulmonary rehabilitation programme amongst patients admitted to a tertiary hospital with chronic obstructive pulmonary disease.Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study.A reduction in the use of volunteered descriptors of air hunger is associated with increased walking distance in people with COPD.A self-management approach using self-initiated action plans for symptoms with ongoing nurse support in patients with Chronic Obstructive Pulmonary Disease (COPD) and comorbidities: the COPE-III study protocol.Can we predict which patients with refractory dyspnea will respond to opioids?Fatigue in COPD: association with functional status and hospitalisations.Hypoxia suppresses symptom perception in asthma.Health, economic, psychological and social impact of educating carers of patients with advanced pulmonary disease (protocol).Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD.The language of breathlessness differentiates between patients with COPD and age-matched adults.Barriers to, and facilitators for, referral to pulmonary rehabilitation in COPD patients from the perspective of Australian general practitioners: a qualitative studyOnce-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group studyResponseEducation in COPD self-management: only part of the gameProviding patients with reviews of evidence about COPD treatments: a controlled trial of outcomesBarriers to success for an evidence-based guideline for chronic obstructive pulmonary diseaseSimplified COPD screening: validation of the PiKo-6® in primary careCombination therapy with long-acting beta-agonists plus inhaled corticosteroids is no more effective than LABA monotherapy for mortality outcomes and severe exacerbations in moderate to very severe COPD and is associated with serious adverse effectsParental and life-course influences on symptomatic airflow obstructionEfficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trialIt is time for the world to take COPD seriously: a statement from the GOLD board of directors
P50
Q24197903-2AEA9347-BD48-4BAC-8F34-D49A45258F2CQ24628047-D191C63B-555D-4138-9CE9-3680C7A5E930Q34102125-08D3E884-337B-4B09-9515-CFCAE2206C07Q34486867-85B9E985-5101-422C-9731-01066E37685DQ34628620-C90FB21D-8974-4691-9B01-3E9659B98EDAQ35055974-1BC31DF8-3862-44B6-8B79-F3C80A53D3C7Q35671691-AE50C99A-F267-4C5A-A33D-B979C0A80FBBQ35905977-6850306C-5AF3-488B-92FB-F117415366EDQ36265136-4A9436D7-9888-4D9A-BF87-A0FA664C2010Q36744116-BD6F755F-8538-45DF-9EBB-3F10AE389C0FQ37211073-6186C188-602E-4398-A79B-24A93CC932EDQ37801157-B7A497A5-3B61-44C2-82FE-EDE64D2DBBBFQ37981714-11C5094E-1FE2-47F8-BEAA-EE05AA611549Q38753103-904512F1-0C47-4978-AFD6-A8CFBE3BB365Q38841833-24EE697B-BE43-4481-A40C-2C7308FB11E6Q38881463-D2FF767D-3CCA-4505-98E0-2F9935F907D1Q39399877-D4BB95EC-5F7E-445A-9485-4DDE144564F3Q39774428-A3210AD0-C16C-4E49-B46A-5A605BE93BBCQ42210687-17D3A890-DA31-404E-8079-38987A0E5CB8Q43581829-20A76C48-1396-4E21-B07D-5CBADF106BC2Q43587824-0B1B3567-78D5-4483-95BF-968C4F7D06D7Q45336597-A4F161F5-41DB-4F5F-B50C-10F5B1408A33Q46883793-6FB9CA51-584F-4E88-9B1A-68F74B22AFFCQ46912389-1D5C4784-A562-45BA-B615-0D21AA81BE83Q47619105-29D84B0F-2D4B-4685-AAB1-3CB8828F57ADQ48006839-514662EA-E475-4018-B755-00959B51ECBDQ48662465-3AB02ED1-6212-4ECF-AFC0-D3E16A356D24Q53433550-440451F0-C32C-4EE9-88B1-A168CDA370C0Q53539773-AEA06F88-54D2-4268-87CD-599F537B226DQ58146872-E9B13C44-C72F-4EE7-B894-AC706A8749DEQ58381887-192FFF1E-869D-4D2B-8F5B-793F7F85EC5EQ58428639-710F126C-CB1D-4636-AB11-3D1D9611E9A6Q64110719-05185BE4-25E6-40E3-84F6-91F538C76B6AQ80132308-8FDE7563-CED3-43D9-A6BC-A897D024B7ADQ81466756-944A4CC3-193D-4510-A920-4F3F6A775149Q84151998-65CFD5B1-048C-4609-A720-B4E47237BF03Q84351928-4DB4D6EC-C9E5-4BA7-B77C-ED9A1DADB6A6Q90182152-00E087AF-C92F-4215-8884-9CD090063F03Q90734981-E5047386-CC49-4266-BCFA-E293C84EEB8DQ91620579-130ADEC0-534A-4019-8F2A-B96FE3735CFC
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Peter A Frith
@ast
Peter A Frith
@en
Peter A Frith
@es
Peter A Frith
@nl
Peter A Frith
@sl
type
label
Peter A Frith
@ast
Peter A Frith
@en
Peter A Frith
@es
Peter A Frith
@nl
Peter A Frith
@sl
prefLabel
Peter A Frith
@ast
Peter A Frith
@en
Peter A Frith
@es
Peter A Frith
@nl
Peter A Frith
@sl
P106
P21
P31
P496
0000-0003-3265-0131